DNP Therapeutics (DNP Tx) is an early-stage therapeutics company based in Cambridge, Massachusetts, incorporated in 2026. It describes itself as leveraging knowledge across multiple fields of biology to bring forward a new generation of treatments for a broad range of unmet medical needs. As of this research the company has disclosed no pipeline, platform, disease area or team publicly — its website is a single landing page with a contact form. Its first SEC Form D reports $470,000 sold to 7 investors against a $1,000,000 offering.